Reagents, kits and assay methods for monoclonal antibodies and cytokeratin 18 fragment assay
By providing a monoclonal antibody with a specific CDR amino acid sequence, the specificity problem of fCK18 detection in existing technologies has been solved, achieving efficient and accurate detection of fCK18, which is suitable for biomarker detection of diseases such as NASH.
Patent Information
- Application Number
- CN202210184476.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-02-22
- Filing Date
- 2022-02-21
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-02-21
AI Technical Summary
The lack of specific antibodies in the current technology that can efficiently detect the cytokeratin 18 fragment (fCK18) makes it difficult to accurately reflect the detection methods of biomarkers for diseases such as non-alcoholic steatohepatitis (NASH) that induce apoptosis.
A novel monoclonal antibody is provided, the heavy and light chains of which contain specific complementarity-determining region (CDR) amino acid sequences that bind with high affinity to fCK18(239-397) and fCK18(261-397) without binding to full-length CK18 or other fragments. This antibody is used to prepare fCK18 assay reagents and kits for detection via a sandwich assay.
It achieves high specificity and high sensitivity detection of fCK18, which can accurately reflect biomarkers of diseases such as NASH, thus improving the accuracy and reliability of detection.
Smart Images

Figure CN114957462B_ABST
Abstract
Description
[Technical Field]
[0001] This invention relates to reagents, kits, and methods for the assay of monoclonal antibodies and cytokeratin 18 fragments. [Background Technology]
[0002] Cytokeratin 18 (hereinafter referred to as "CK18") is cleaved by caspase during apoptosis of epithelial cells such as hepatocytes, resulting in CK18 fragments (hereinafter referred to as "fCK18"). For example, fCK18 in the blood cleaved by caspase 3 is known as a biomarker for diseases such as non-alcoholic steatohepatitis (hereinafter referred to as "NASH") and cancer that induce apoptosis. As a method for detecting fCK18, Patent Document 1 is known. Patent Document 1 discloses a monoclonal antibody that binds to a portion of the C-terminus of fCK18 for the purpose of detecting fCK18.
[0003] [Existing Technical Documents]
[0004] [Patent Documents]
[0005] [Patent Document 1] US Patent No. 6,296,850 Specification
[0006] [Summary of the Invention]
[0007] [The problem the invention aims to solve]
[0008] The present invention aims to provide novel antibodies that bind to fCK18. Furthermore, the present invention aims to provide reagents for fCK18 assay containing said antibody, kits containing reagents for fCK18 assay, and methods for measuring fCK18 using said antibody.
[0009] [Methods used to solve problems]
[0010] This invention provides a novel monoclonal antibody that binds to fCK18, which is a single monoclonal antibody containing a heavy chain and a light chain. The heavy chain contains CDR1, CDR2 and CDR3, each composed of the amino acid sequences shown in SEQ ID NO:1, 2 and 3, and the light chain contains CDR1, CDR2 and CDR3, each composed of the amino acid sequences shown in SEQ ID NO:4, 5 and 6.
[0011] In addition, the present invention provides a reagent for fCK18 assay containing the antibody, a kit containing the assay reagent, and a method for measuring fCK18 using the antibody as a capture or detection agent.
[0012] [The effects of the invention]
[0013] According to the present invention, a novel monoclonal antibody that binds to fCK18 is provided.
[0014] [Brief explanation of the attached image]
[0015]
【 Figure 1A [Illustration] is a schematic diagram showing an example of the kit according to this embodiment.
[0016]
【 Figure 1B [Illustration] is a schematic diagram showing an example of the kit according to this embodiment.
[0017]
【 Figure 2 The results are from the IP-blotting of K18-624 antibody, M30 antibody, and fCK18 (239-397) in Example 2.
[0018]
【 Figure 3 [Image] is the result of Western blotting of the soluble and insoluble fractions in the purification process of recombinant fCK18 (241-397) in Example 3.
[0019]
【 Figure 4 The results are Western blots of the soluble and insoluble fractions from the purification process of recombinant fCK18 (261-397) in Example 3.
Detailed Implementation Methods
[0020] [1. Monoclonal antibody]
[0021] The antibody of this embodiment is a single monoclonal antibody containing a heavy chain and a light chain, each of which has three complementarity-determining regions (hereinafter referred to as "CDRs") in its variable regions. The three CDRs are designated as CDR1, CDR2, and CDR3 from the amino terminus of the antibody chain. The antibody of this embodiment contains CDRs having the following amino acid sequence.
[0022] <Amino acid sequence of the CDR of the antibody in this embodiment>
[0023] Heavy chain CDR1: SFGMH (SEQ ID NO:1)
[0024] Heavy chain CDR2: YISSGSTTIY YADTVKG (SEQ ID NO:2)
[0025] Heavy chain CDR3: RGMITTGAWF AY (SEQ ID NO:3)
[0026] • Light chain CDR1: RASQRIGTSI H (SEQ ID NO:4)
[0027] • Light chain CDR2: YASESIS (SEQ ID NO:5)
[0028] Light chain CDR3: QQSYIWPFT (SEQ ID NO:6)
[0029] The heavy chain of the antibody in this embodiment preferably contains the amino acid sequence shown in SEQ ID NO:7. The light chain of the antibody in this embodiment preferably contains the amino acid sequence shown in SEQ ID NO:8. One embodiment of the antibody comprises a heavy chain having the amino acid sequence shown in SEQ ID NO:7 and a light chain having the amino acid sequence shown in SEQ ID NO:8.
[0030] <Amino acid sequence of the variable region of the antibody in this embodiment>
[0031] Variable region of heavy chain
[0032] DVQLVESGGG LVQPGGSRKL SCAASGFTFS SFGMHWVRQA PEKGLEWVAY ISSGSTTIYYADTVKGRFTI SRDNPKNTLF LQMTSLRSED TAMYYCARRG MITTGAWFAY WGQGTLVTVS A(SEQ IDNO:7)
[0033] Variable regions of light chains
[0034] DILLTQSPAI LSVSPGERVS FSCRASQRIG TSIHWYQQRT NGSPRLLIKY ASESISGIPSRFSGSGSGTD FTLSINSVES EDIADYYCQQ SYIWPFTFGS GTKLEIK(SEQ ID NO:8)
[0035] In the prior art, the CDR sequences of the heavy and light chains can be determined from a public database for determining CDR sequences based on the amino acid sequence of the variable region of the antibody. Examples of such databases include VBASE2 (Reter I, Nucleic Acids Res. 2005). The CDR sequence of the antibody in this embodiment is a sequence determined by VBASE2.
[0036] CK18 is one of the intermediate choroidal fibers that form the cytoskeleton of epithelial cells. In this specification, CK18 refers to human cytokeratin 18. The amino acid sequence of full-length CK18 (hereinafter referred to as "full-length CK18") is shown in the amino acid sequence of SEQ ID NO:9. Full-length CK18 is digested by enzymes into fragments of various lengths. As fCK18 digested by enzymes, the existence of, for example, fCK18(1-239), fCK18(239-430), and fCK18(239-397) has been confirmed (Carlos, The Journal of Cellbiology 138.6(1997): 1379-1394.). Furthermore, in this specification, in SEQ ID NO:9, fCK18 of the amino acid sequence X to Y is represented as fCK18(XY). Wherein, X and Y represent any natural number less than 430 that does not contain 0, and X is a smaller number than Y. For example, fCK18 of the amino acid sequence from position 239 to position 397 of SEQ ID NO:9 is represented as fCK18(239-397).
[0037] As described in the examples below, it is considered important that the C-terminal amino acid sequence of the antigen is an aspartic acid residue for the antibody of this embodiment to bind to the antigen. Therefore, the antibody of this embodiment shows binding to fCK18(239-397) and fCK18(261-397) within CK18, but substantially does not show binding to full-length CK18 and fCK18(239-396).
[0038] The phrase "substantially showing no binding" includes not only complete non-binding but also binding to a degree that does not affect the assay results in immunoassays using the antibody of this embodiment. For example, it is less than 1 / 50th of the binding between the antibody of this embodiment and fCK18 (381-397). In a more preferred example, it is less than 1 / 100th, and in a further preferred example, it is less than 1 / 150th. The binding between the antibody and the antigen can be determined by methods known in the art. Examples of such methods include immunoassay, immunoblotting, surface plasmon resonance analysis, and isothermal titration calorimetry analysis.
[0039] The antibody in this embodiment can also be a humanized antibody whose variable region of the heavy chain has heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each having an amino acid sequence shown in SEQ ID NO:1, 2, and 3, and whose variable region of the light chain has light chain CDR1, light chain CDR2, and light chain CDR3 each having an amino acid sequence shown in SEQ ID NO:4, 5, and 6. A humanized antibody is an antibody obtained by transplanting the gene sequence of a CDR of a non-human antibody into a human antibody gene (CDR transplantation). Alternatively, the antibody involved in this embodiment can also be a chimeric antibody having a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:7 and a light chain variable region having an amino acid sequence shown in SEQ ID NO:8. A chimeric antibody is an antibody that links the variable region and constant region of antibodies derived from different species.
[0040] The antibody class in this embodiment can be any of IgG, IgA, IgM, IgD, and IgE, but IgG is preferred. The subclass of IgG is not particularly limited and can be any of IgG1, IgG2, IgG3, and IgG4. In this specification, "antibody" refers not only to the form of an immunoglobulin but also to antibody fragments. Examples of such antibody fragments include Fab, F(ab')2, Fab', Fv, Fd, domain antibodies (dAb), single-chain antibodies (scFv), and biantibodies.
[0041] The antibody in this embodiment can also be modified with labeling substances known in the prior art. Such labeling substances are not particularly limited as long as they generate a detectable signal. Examples include substances that generate a signal themselves (hereinafter also referred to as "signal generating substances") and substances that catalyze the reaction of other substances to generate a signal. Examples of signal generating substances include fluorescent substances, radioactive isotopes, and chromogenic substances. Examples of substances that catalyze the reaction of other substances to generate a detectable signal include, for example, enzymes. Examples of fluorescent substances include fluorescent dyes such as fluorescein isothiocyanate (FITC), rhodamine, and Alexa Fluor (registered trademark), and fluorescent proteins such as GFP. Examples of radioactive isotopes include… 125 I, 14 C 32 P, etc. Examples of chromogenic substances include metal colloids such as gold nanoparticles. Examples of enzymes include alkaline phosphatase, peroxidase, β-galactosidase, glucosidase, polyphenol oxidase, tyrosinase, acid phosphatase, and luciferase.
[0042] [2. Antibody Production Methods]
[0043] The antibody of this embodiment can be obtained by known methods of monoclonal antibody production, such as hybridoma method, phage display method, and genetic engineering method. When producing the hybridoma that generates the antibody of this embodiment by hybridoma method, fCK18 can be used as the immunogen. Specifically, the polypeptide shown in fCK18 (381-397) is exemplified. The method of polypeptide synthesis is known itself, and examples include, for example, Fmoc solid-phase synthesis. When the immunogenicity of the synthesized polypeptide is low, it is preferable to bind it to a carrier protein such as keyhole-hemocyanin (KLH) or albumin. When synthesizing the peptide by cross-linking the carrier protein, it is preferable to attach a cysteine residue to the N-terminus or C-terminus of the polypeptide sequence at the time of polypeptide synthesis. Alternatively, the immunogen can also be prepared as a recombinant protein. The recombinant fCK18(X-397) (hereinafter also referred to as "rfCK18(X-397)") can be obtained by integrating a polynucleotide encoding the amino acid sequence of fCK18(X-397) into a known expression vector, transforming host cells with this vector to express rfCK18(X-397), and then purifying it using known methods.
[0044] Next, mice are immunized with the prepared polypeptide, and antibody-producing cells, such as spleen cells, are obtained from the immunized mice. Then, according to a known method for preparing hybridomas described in Kohler and Milstein, Nature, vol. 256, pp. 495-497, 1975, the obtained antibody-producing cells are fused with suitable myeloma cells to obtain a hybridoma. In the screening of the hybridoma, a synthetic polypeptide for use as an immunogen can be used. The antibody of this embodiment can be obtained from the culture supernatant of the hybridoma or from the ascites fluid of a mammal that has received the hybridoma intraperitoneally. The obtained antibody can also be purified by known methods such as salting out, affinity chromatography, and gel filtration.
[0045] When preparing the hybridoma that produces the antibody of this embodiment, the analysis can be performed as described in Example 1 below. Specifically, firstly, using RNA extracted from the hybridoma, a polynucleotide encoding the antibody of this embodiment is synthesized by reverse transcription and RACE (Rapid Amplification of cDNA Ends). Then, the base sequence of the synthesized polynucleotide is analyzed by sequencing, and the amino acid sequence of the antibody is determined based on its base sequence.
[0046] When preparing the antibody of this embodiment using phage display, for example, a Fab clone can be prepared. First, an animal such as a mouse is immunized with the synthetic polypeptide described above, and mRNA is obtained from the spleen of the animal to synthesize cDNA. The obtained cDNA is amplified using primers known for cloning antibody genes to prepare a Fab phage library. The obtained library can be used to obtain a Fab clone of the antibody of this embodiment using the known Fab phage display method and biopanning (Philippa M. O'Brien and Robert Aitken, Antibody Phage Display, (2002) Methods in Molecular Biology Volume No. 178, see below).
[0047] When producing the antibody of this embodiment using genetic engineering methods, examples include methods using host cell synthesis lines or cell-free protein synthesis lines using artificial tRNA. When using a host cell synthesis line, it can be produced using a vector containing a single polynucleotide encoding the antibody of this embodiment and a host cell containing the vector. Specifically, a polynucleotide encoding the amino acid sequence of the antibody of this embodiment can be integrated into a known expression vector, and after transforming host cells with this vector to express the antibody of this embodiment, it can be purified using known methods. Furthermore, the type of vector is not particularly limited, and vectors known in the prior art, such as expression vectors, cloning vectors, and viral vectors, can be appropriately selected. Additionally, the type of host cell is not particularly limited, and eukaryotic cells, prokaryotic cells, mammalian cells, etc., can be appropriately selected.
[0048] When using a cell-free protein synthesis system, synthesis can be achieved by adding amino acids, energy molecules (e.g., ATP, GTP, etc.), and polynucleotides encoding the amino acid sequence of the antibody of this embodiment to a cell extract containing translation factors. Cell extracts containing translation factors can be, for example, those from Escherichia coli, yeast, rabbit reticulocytes, wheat germ, insect cells, or mammalian cultured cells.
[0049] [3. Reagents]
[0050] One embodiment of the present invention is a reagent for fCK18 assay. This reagent contains the antibody described in the embodiment [1. Monoclonal antibody] above. In the reagent of this embodiment, the fCK18 to be measured is not particularly limited as long as it is an fCK18 detectable by the antibody. Examples of such fCK18 include fCK18(239-397), fCK18(241-397), fCK18(261-397), etc.
[0051] The form of the reagent in this embodiment is not particularly limited, and it may be a solid (e.g., powder, crystals, freeze-dried product, etc.) or a liquid (e.g., solution, suspension, emulsion, etc.). When the reagent is a liquid, the solvent is not particularly limited as long as it can stably preserve the antibody of this embodiment. Examples of solvents include water, physiological saline, phosphate-buffered saline (PBS), Tris-buffered saline (TBS), good buffers, and combinations thereof. Examples of good buffers include MES, Bis-Tris, ADA, PIPES, Bis-Tris-propane, ACES, MOPS, MOPSO, BES, TES, HEPES, HEPPS, Tricine, Tris, Bicine, TAPS, etc.
[0052] The reagent in this embodiment may also contain known additives. Examples of additives include, for instance, protein stabilizers such as bovine serum albumin (BSA), preservatives such as sodium azide, inorganic salts such as sodium chloride, and combinations thereof.
[0053] [4. Reagent Kit]
[0054] One embodiment of the present invention is a kit for fCK18 assay. This kit contains a reagent containing a capture body and a reagent containing a detector, either the capture body or the detector containing an antibody as described in [1. Monoclonal Antibody]. The capture body preferably binds to a site different from the binding site of the detector in fCK18.
[0055] In one embodiment, the capture body contains the antibody described in [1. Monoclonal antibody]. In this embodiment, the detection body is not particularly limited as long as it can bind to fCK18, but it is preferable to bind to a site in fCK18 different from that of the capture body. The detection body may contain antibodies, aptamers, etc.
[0056] In another embodiment, the detector contains the antibody described in [1. Monoclonal Antibody]. In this embodiment, the capture body is not particularly limited as long as it can bind to fCK18, but it is preferable to bind to a site in fCK18 different from that of the detector. In this embodiment, the capture body preferably binds to fCK18 (239-397), and more preferably to a site in fCK18 (239-397) different from that of the detector. The capture body may contain antibodies, aptamers, etc. The detector body is, in this case, the antibody described in [1. Monoclonal Antibody] is a first antibody, and may also contain a labeling substance and a second antibody that binds to the first antibody.
[0057] The kit of this embodiment may also include a solid phase for immobilizing the capture antibody. The solid phase can be any insoluble carrier capable of immobilizing the capture antibody. The method of immobilizing the capture antibody onto the solid phase is not particularly limited. For example, the capture antibody and the solid phase can be directly bonded or indirectly bound via other substances. Examples of direct binding include physical adsorption. Examples of indirect binding include combinations of biotinylate (biotin analogs such as biotin and desminopeptidase) and avidin (avidin analogs such as avidin, streptavidin, and tamavidin). In this case, by pre-modifying the capture antibody with biotinylate and pre-binding the solid phase with avidin, the capture antibody can be indirectly bound to the solid phase via the binding of biotinylate and avidin.
[0058] The raw materials for the solid phase are not particularly limited; for example, they can be selected from organic polymers, inorganic compounds, and biological polymers. Examples of organic polymers include latex, polystyrene, and polypropylene. Examples of inorganic compounds include magnetic materials (iron oxide, chromium oxide, and ferrite, etc.), silicon oxide, alumina, and glass. Examples of biological polymers include insoluble agarose, insoluble dextran, gelatin, and cellulose. Two or more of these can also be used in combination. The shape of the solid phase is not particularly limited; examples include microplates, microtubes, test tubes, particles, and membranes. Among these, microplates and particles (especially magnetic particles) are preferred.
[0059] In fCK18, the antibody that binds to a different site than the antibody described in [1. Monoclonal Antibodies] is not particularly limited; for example, commercially available antibodies can be used. Examples include: M5 Keratin 18Mab (clone name: M5, hereinafter referred to as "M5 antibody") (Diapharma Corporation), M6 Keratin 18Mab (clone name: M6, hereinafter referred to as "M6 antibody"), etc.
[0060] The kit of this embodiment may also contain a calibrator for fCK18. The fCK18 contained in the calibrator may be a recombinant or a synthetic peptide. For example, fCK18(239-397), fCK18(241-397), fCK18(261-397), etc., may be used as the fCK18 contained in the calibrator. From the viewpoint of expression efficiency, recombinant fCK18(261-397) is suitable when preparing the recombinant fCK18.
[0061] The calibrator of this embodiment contains multiple reagents, each containing fCK18, and the concentrations of fCK18 in the multiple reagents are preferably different from each other. This calibrator may also, for example, include a buffer solution (negative control) without fCK18 and a buffer solution containing a known concentration of fCK18. One embodiment of the calibrator includes at least three containers: the first container contains a buffer solution without fCK18, the second container contains a first fCK18 solution, and the third container contains a second fCK18 solution. In this embodiment, the fCK18 concentrations of the first and second fCK18 solutions are different.
[0062] The number of reagents contained in the calibrators in the kit of this embodiment is not particularly limited, and can be selected from, for example, 2, 3, 4, 5, and 6 or more. The fCK18 concentration of the calibrator can be used to determine the fCK18 concentration in the test subject, and is not particularly limited.
[0063] The form of the reagents included in the kit of this embodiment is not particularly limited, and they may be solids (e.g., powders, crystals, lyophilized products, etc.) or liquids (e.g., solutions, suspensions, emulsions, etc.). When the reagents are liquids, the solvent is not particularly limited as long as it can stably preserve the antibody of this embodiment. The details of such solvents are the same as those described in [3. Reagents].
[0064] The reagents contained in the kit of this embodiment may also contain known additives. Examples of additives include, for instance, protein stabilizers such as bovine serum albumin (BSA), preservatives such as sodium azide, and inorganic salts such as sodium chloride.
[0065] An example of the kit described in this embodiment is shown in Figure 1A .exist Figure 1A In this document, 11 represents the kit, 12 represents the first container holding the first reagent containing the capture antibody, 13 represents the second container holding the reagent containing the detector antibody, 14 represents the packaging box, and 15 represents the accompanying documentation. The accompanying documentation may describe the composition, usage, and storage methods of each reagent. In this example kit, other reagents may be included. Examples of such reagents include, for instance, a solid phase for immobilizing the capture antibody, a buffer solution, and a calibrator.
[0066] An example of the kit for implementation is shown in Figure 1B .exist Figure 1BIn this kit, 21 represents the kit, 22 represents the first container containing the first reagent containing the antibody described in [1. Monoclonal Antibody], 23 represents the second container containing the reagent containing the detector, and 24 and 25 represent the third and fourth containers containing the calibrator reagent containing fCK18, respectively. The fCK18 concentrations of the calibrator reagents contained in the third container 24 and the fourth container 25 are different from each other. 26 represents the accompanying documentation, and 27 represents the packaging box. This kit contains the first reagent containing the antibody described in [1. Monoclonal Antibody], the reagent containing the detector, and the calibrator for quantifying fCK18, and may contain other reagents. Examples of such reagents include, for example, a solid phase for immobilizing the capture antibody, a buffer solution, and a calibrator reagent with a different fCK18 concentration than the aforementioned calibrator reagents.
[0067] [5. Determination method of fCK18]
[0068] One embodiment of the present invention is a method for determining fCK18 in a test subject. This method includes a step of forming a complex (hereinafter also referred to as a "sandwich complex") containing a trap, fCK18 in the test subject, and a detector on a solid phase, and a step of determining fCK18 in the test subject based on the detector contained in the complex. Furthermore, it is a method for determining fCK18 in a test subject, wherein the antibody contained in the trap or detector is the antibody described in [1. Monoclonal Antibodies].
[0069] The test subject in this embodiment is a sample containing fCK18 or a sample suspected of containing fCK18. As the test subject, biologically derived samples, samples pretreated from biologically derived samples, cell culture extracts, cell extracts, etc., can be used. Examples include whole blood, serum, plasma, bone marrow fluid, semen, tissue, tissue fluid, lymph, etc. When the test subject contains insoluble impurities such as cells, the impurities can be removed from the test subject by known means such as centrifugation or filtration. Furthermore, the test subject can be diluted with a suitable aqueous medium as needed. Such an aqueous medium is not particularly limited as long as it does not interfere with the determination described later; examples include water, physiological saline, buffer solutions, etc. The buffer solution is not particularly limited as long as it has a buffering effect at a pH near neutral (e.g., pH 6 to 8). Examples of such buffer solutions include good buffers of HEPES, MES, PIPES, TBS, PBS, etc.
[0070] The measurement method of this embodiment may also include a step of contacting the solid phase, the trap, the fCK18 in the test sample, and the detector in the formation step. In this case, a composite may also be formed on the solid phase by contacting the solid phase with the trap pre-fixed, the fCK18 in the test sample, and the detector in the formation step.
[0071] In the contact process of this embodiment, the contact order of the solid phase, the trap, fCK18, and the detector is not particularly limited. However, it is preferable to contact fCK18 with the trap to form a composite of the test substance and the trap in the test body, then contact the composite with the solid phase to form a composite on the solid phase, and then contact the composite with the detector to form a sandwich composite on the solid phase.
[0072] Preferably, after forming a complex of the test substance and the trap on a solid phase, B / F separation is performed to remove unreacted components before contacting the detector. Unreacted free components refer to components that do not form the complex. Examples include trap antibodies and detection antibodies that do not bind to fCK18. The method of B / F separation is not particularly limited. When the solid phase is particles, B / F separation can be performed by centrifuging to recover only the solid phase containing the trap complex. When the solid phase is a container such as a microplate or microtube, B / F separation can be performed by removing the liquid containing unreacted free components. In addition, when the solid phase is magnetic particles, B / F separation can be performed by removing the liquid containing unreacted free components from the nozzle while the magnetic particles are magnetically confined by a magnet, which is preferred from an automation point of view. Alternatively, after removing the unreacted free components, the solid phase containing the trap complex can be washed with a suitable aqueous medium such as PBS.
[0073] The fCK18 value in the test subject can be obtained by detecting the complex formed on the solid phase using methods known in the art. For example, when using an antibody labeled with a labeled substance as a detection antibody, the fCK18 value can be obtained by detecting the signal generated by the labeled substance. Alternatively, the fCK18 value can also be obtained by using a labeled second antibody against the detection antibody.
[0074] In this specification, "detection signal" includes qualitative detection of the presence or absence of a signal, quantitative detection of signal strength, and semi-quantitative detection of signal strength. Semi-quantitative detection refers to representing signal strength in stages, such as "no signal," "weak," "medium," and "strong." In this embodiment, quantitative or semi-quantitative detection of signal strength is preferred.
[0075] The method for detecting the signal is known in the prior art. In this embodiment, any method suitable for selecting the type of signal originating from the labeled substance described above is acceptable. For example, when the labeled substance is an enzyme, the signal of light, color, etc., generated by reacting the substrate with the enzyme can be measured using a known device such as a spectrophotometer.
[0076] The substrate for an enzyme can be appropriately selected from known substrates, corresponding to the type of enzyme. For example, when using alkaline phosphatase as an enzyme, substrates that can be cited include chemiluminescent substrates such as CDP-Star (4-chloro-3-(methoxyspiro[1,2-dioxane-3,2'-(5'-chloro)tricyclo[3.3.1.13,7]decane]-4-yl)phenyl phosphate 2 sodium, CSPD (3-(4-methoxyspiro[1,2-dioxane-3,2-(5'-chloro)tricyclo[3.3.1.13,7]decane]-4-yl)phenyl phosphate 2 sodium, chromogenic substrates such as 5-bromo-4-chloro-3-indole phosphate (BCIP), 5-bromo-6-chloro-indole phosphate 2 sodium, and p-nitrophenyl phosphate. In addition, when peroxidase is used as an enzyme, examples of substrates include chemiluminescent substrates such as LUMINOR and its derivatives, and chromogenic substrates such as 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate ammonium) (ABTS), 1,2-phenylene diamine (OPD), and 3,3',5,5'-tetramethylbenzidine (TMB).
[0077] When the labeled substance is a radioactive isotope, the radiation as a signal can be measured using a known device such as a scintillation counter. Furthermore, when the labeled substance is a fluorescent substance, the fluorescence as a signal can be measured using a known device such as a fluorescence microplate reader. Moreover, the excitation wavelength and fluorescence wavelength can be appropriately determined according to the type of fluorescent substance used.
[0078] The signal detection result can be used as the fCK18 measurement result. For example, when quantifying the signal intensity, the measured value of the signal intensity itself or the value obtained from that measurement can be used as the fCK18 measurement result. Examples of values obtained from the measured signal intensity include, for example, the value obtained by subtracting the measured value of a negative control sample or the background value from that measured value. Alternatively, the measured signal intensity value can be applied to a calibration curve to determine the amount or concentration of human fCK18. A suitable negative control sample can be selected, for example, a biological sample obtained from a healthy person.
[0079] The measurement method of this embodiment may also include a step of measuring the concentration of fCK18 in the calibrator using the calibrator described above, and a step of obtaining the concentration of fCK18 in the test subject based on the measured concentration.
[0080] In the measurement method of this embodiment, the concentration of fCK18 in the test body can be obtained from the measured value of fCK18 in the calibrator and the measured value of fCK18 in the test body.
[0081] Since the concentration of fCK18 in the calibrator is known, the concentration of fCK18 in the test subject can be calculated from the measured value of fCK18 in the test subject based on the measured value of fCK18 in the calibrator. In a preferred embodiment, a calibration curve is constructed from the measured values of fCK18 in the calibrator, and the concentration of fCK18 in the test subject is calculated based on the calibration curve and the measured value of fCK18 in the test subject. The calibration curve can be constructed, for example, by plotting the measured values of fCK18 in multiple calibrators on an XY plane with the concentration of fCK18 in the calibrator on the X-axis and the measured values on the Y-axis, and obtaining a straight line or curve using known methods such as the least squares method. The concentration of fCK18 in the test subject can be obtained by using a calibration curve suitable for constructing the measured value of fCK18 in the test subject.
[0082] In this embodiment, commercially available fully automated immunoassay devices can also be used to detect fCK18 in the test subjects. Examples of fully automated immunoassay devices include the HISCL (trademark) series (Sysmex Corporation).
[0083]
Example
[0084] The present invention will now be described in detail with reference to the embodiments, but the present invention is not limited to these embodiments.
[0085] [Example 1: Obtaining Antibodies]
[0086] [1] Obtaining hybridomas
[0087] Hybridomas were obtained by generating antibodies from mouse spleens. Specifically, peptide 1 (SEQ ID NO: 10) described in Table 1 was synthesized, conjugated with KLH, and immunized by intraperitoneal injection five times and intravenous injection once into Balb / C mice with an emulsion mixed with adjuvant. Freund's complete adjuvant was used initially, and Freund's incomplete adjuvant was used in subsequent booster immunizations. The immunogen was set as the full-length recombinant CK18 shown in SEQ ID NO: 9 (hereinafter also referred to as "full-length rCK18"), and immunization was performed by intraperitoneal injection four times and intravenous injection twice, in the same manner as above. Three days after the final immunization, the spleen was removed from the mice, and spleen cells were isolated. Subsequently, hybridomas were obtained by fusing the obtained spleen cells with mouse myeloma cells (P3-X63-Ag8.653).
[0088] [2] Filtering
[0089] The reactivity of the hybridomas obtained from [1] above with peptide 1, peptide 2 and full-length rCK18 (produced by PROSPEC) listed in Table 1 will be determined by the following screening method (solid phase ELISA).
[0090] Table 1
[0091] Peptide name Amino acid sequence (N-terminus → C-terminus) Serial Number Peptide 1 RRLLEDGEDF NLGDALD 10 Peptide 2 RRLLEDGEDF NLGDAL 11
[0092] <Filtering Method 1>
[0093] (1) Add 2.5 μg / mL of ANTI pentaHIS antibody to the ELISA plate at 50 μL / well, and immobilize it by standing at 4℃ overnight. Then wash the plate three times with PBST, add 200 μL / well of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0), and store the plate at 4℃ overnight.
[0094] (2) The antigen dilution solution was prepared by diluting the full-length rCK18 with buffer I' (10mM NaH2PO4·2H2O, 149.7mM NaCl, 2.5mM EDTA·2Na, 0.10% BSA, pH7.0) to a final concentration of 0.2μg / mL.
[0095] (3) Wash the plate three times with PBST, add 50 μL of each antigen diluent to each well, and shake for 45 minutes.
[0096] (4) Wash the plate three times with PBST, add 50 μL of culture supernatant to each well, and shake for 45 minutes.
[0097] (5) Wash the plate three times with PBST, add 50 μL of Affinipure F(ab)'2 fragment conjugated with peroxidase diluted 15,000 times to goat anti-mouse IgG (H+L) (Jackson) to each well, and shake for 45 minutes.
[0098] (6) Wash the plate three times with PBST, add 100 μL / well of TMB Mix (1-step Ultra TMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15:0.15:14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction.
[0099] (7) Use a plate reader to measure the absorbance of the reaction solution at 450 nm.
[0100] <Filtering Method 2>
[0101] (1) Add BSA to the N-terminus of peptide 1 and peptide 2.
[0102] (2) Add 5 μg / mL of each peptide to 100 μL / well of the ELISA plate and incubate at 4°C overnight to immobilize. Then wash the ELISA plate three times with PBST and add 200 μL / well of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0) to prepare the plate and store it at 4°C overnight.
[0103] (3) Wash the plate three times with PBST, add 100 μL of culture supernatant to each well, and shake for 1 hour.
[0104] (4) Wash the plate three times with PBST, add 100 μL of Affinipure F(ab)'2 fragment conjugated with peroxidase diluted 15,000 times to goat anti-mouse IgG (H+L) (Jackson) to each well, and shake for 1 hour.
[0105] (5) Wash the plate three times with PBST, add 100 μL / well of TMB Mix (1-step Ultra TMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15:0.15:14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction.
[0106] (6) Use a plate reader to measure the absorbance of the reaction solution at 450 nm.
[0107] Four hybridomas were selected that produced antibodies that showed reactivity to full-length rCK18 or peptide 1.
[0108] [3] Epitope analysis of selected antibodies
[0109] The reactivity of three antibodies (hereinafter referred to as "K18-91 antibody", "K18-287 antibody", and "K18-328 antibody", respectively) generated from hybridomas that produced antibodies reactive to full-length rCK18 and the synthetic peptides listed in Table 2 was determined by solid-phase ELISA. Additionally, the reactivity of the antibody (hereinafter referred to as "K18-624 antibody") generated from hybridomas that produced antibodies reactive to peptide 1 and peptides 25, 26, and 27 was determined by solid-phase ELISA.
[0110] <Method>
[0111] (1) Synthesize the peptides listed in Table 2 and attach biotin to the N-terminal side.
[0112] (2) Dissolve the synthesized peptide in 80% DMSO solution and then dilute it with PBST to 1 μg / ml.
[0113] (3) After washing the ELISA plate three times with PBST, add 100 μL of biotinylated peptide per well and let it stand at room temperature for 1 hour to immobilize the peptide. Then wash the plate three times with PBST and add 200 μL of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0) per well. Prepare the plate and store it at 4°C overnight.
[0114] (4) Wash the plate three times with PBST, add 50 μL of antibody diluted to 2 μg / ml to each well, and shake at room temperature for 1 hour.
[0115] (5) Wash the plate three times with PBST, and add 50 μL of anti-mouse IgG POD antibody diluted about 5000 times with buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0) to each well, and shake at room temperature for 1 hour.
[0116] (6) Wash the plate three times with PBST, add 100 μL / well of TMB Mix (1-step Ultra TMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15:0.15:14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction. (7) Measure the absorbance of the reaction solution at 450 nm using a plate reader.
[0117] Table 2
[0118] Peptide name Amino acid sequence (N-terminus → C-terminus) Serial Number Peptide 3 APKSQDLAKI MADIRAQY 12 Peptide 4 LAKIMADIRA QYDELARK 13 Peptide 5 DIRAQYDELA RKNREELD 14 Peptide 6 DELARKNREE LDKYWSQQ 15 Peptide 7 NREELDKYWS QQIEESTT 16 Peptide 8 KYWSQQIEES TTVVTTQS 17 Peptide 9 IEESTTVVTT QSAEVGAA 18 Peptide 10 VVTTQSAEVG AAETTLTE 19 Peptide 11 AEVGAAETTL TELRRTVQ 20 Peptide 12 ETTLTELRRT VQSLEIDL 21 Peptide 13 LRRTVQSLEI DLDSMRNL 22 Peptide 14 SLEIDLDSMR NLKASLEN 23 Peptide 15 DSMRNLKASL ENSLREVE 24 Peptide 16 KASLENSLRE VEARYALQ 25 Peptide 17 SLREVEARYA LQMEQLNG 26 Peptide 18 ARYALQMEQL NGILLHLE 27 Peptide 19 MEQLNGILLH LESELAQT 28 Peptide 20 ILLHLESELA QTRAEGQR 29 Peptide 21 SELAQTRAEG QRQAQEYE 30 Peptide 22 RAEGQRQAQE YEALLNIK 31 Peptide 23 QAQEYEALLN IKVKLEAE 32 Peptide 24 ALLNIKVKLE AEIATYRR 33 Peptide 25 VKLEAEIATY RRLLEDGE 34 Peptide 26 IATYRRLLED GEDFNLGD 35 Peptide 27 LLEDGEDFNL GDALD 36
[0119] (result)
[0120] The results for the assays of K18-91, K18-287, and K18-328 antibodies are shown in Tables 3–5. The results for the assay of K18-624 antibody are shown in Table 6. K18-91 antibody showed reactivity with peptide 4. K18-287 and K18-328 antibodies showed reactivity with peptide 17. It is also noted that K18-328 antibody showed higher reactivity with peptide 17 compared to K18-287 antibody. K18-624 antibody showed reactivity with peptide 27.
[0121] Table 3
[0122] Abs450 Peptide 3 4 5 6 7 8 9 10 K18-91 antibody 0.07 1.96 0.02 0.03 0.02 0.00 0.00 0.00 K18-287 antibody 0.04 0.00 -0.01 0.02 0.00 0.00 -0.01 0.00 K18-328 antibody 0.04 0.01 -0.01 0.01 0.00 -0.01 -0.01 0.00
[0123] Table 4
[0124] Abs450 Peptide 11 12 13 14 15 16 17 18 K18-91 antibody 0.02 0.03 0.02 0.00 0.00 -0.01 0.02 0.02 K18-287 antibody 0.00 0.00 0.00 -0.01 -0.02 -0.04 1.05 0.01 K18-328 antibody 0.01 0.00 0.01 -0.01 0.00 -0.04 1.55 0.02
[0125] Table 5
[0126] Abs450 Peptide 19 20 21 22 23 24 25 26 27 K18-91 antibody 0.02 0.01 0.02 0.03 0.05 0.02 0.02 0.02 0.08 K18-287 antibody 0.01 0.00 0.01 0.00 0.03 0.02 0.01 0.02 0.00 K18-328 antibody 0.01 0.00 0.01 0.00 0.02 0.01 0.01 0.01 0.00
[0127] Table 6
[0128] Abs450 Peptide 25 26 27 K18-624 antibody 0.14 0.14 2.34
[0129] [4] Analysis using rCK18, rfCK18 and epitopes of peptides 1 and 2
[0130] The reactivity of K18-328 and K18-624 antibodies to full-length rCK18, the recombinant peptide consisting of amino acid residues 127-430 as shown in SEQ ID NO:9 (hereinafter referred to as "rfCK18(127-430)") (SEQ ID NO:37) (Proteintech), and the recombinant peptide consisting of amino acid residues 239-396 as shown in SEQ ID NO:9 (hereinafter referred to as "rfCK18(239-396)") (SEQ ID NO:38) (Cloud-Clone-Corp) was determined by solid-phase ELISA.
[0131] <Method>
[0132] (1) Add 2.5 μg / mL of ANTI GST antibody or penta HIS antibody to the ELISA plate at 50 μL / well, and incubate at 4℃ overnight to immobilize. Then wash the plate three times with PBST, add 200 μL / well of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0), and store the plate at 4℃ overnight.
[0133] (2) Dilute the full-length rCK18 to a final concentration of 0.2 μg / mL and the rfCK18(127-430) and rfCK18(239-396) to a final concentration of 0.3 μg / mL with buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0) to prepare the antigen dilution solutions.
[0134] (3) Wash the plate three times with PBST, add 50 μL of each antigen diluent, and shake for 45 minutes.
[0135] (4) Prepare K18-328 antibody solution and K18-624 antibody solution to 5-10 ng / mL.
[0136] (5) Wash the plate three times with PBST, add 50 μL of K18-328 antibody solution or K18-624 antibody solution to each well, and shake for 45 minutes.
[0137] (6) Wash the plate three times with PBST, add 50 μL of Affinipure F(ab)'2 fragment conjugated with peroxidase diluted 15,000 times to goat anti-mouse IgG (H+L) (Jackson) to each well, and shake for 45 minutes.
[0138] (7) Wash the plate three times with PBST, add 100 μL / well of TMB Mix (1-step Ultra TMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15:0.15:14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction.
[0139] (8) Use a plate reader to measure the absorbance of the reaction solution at 450 nm.
[0140] Next, the reactivity of K18-328 antibody and K18-624 antibody to peptide 1 and peptide 2 was determined by solid-phase ELISA.
[0141] <Method>
[0142] (1) Add BSA to the N-terminus of peptide 1 and peptide 2.
[0143] (2) Add 5 μg / mL of each peptide to 100 μL / well of the ELISA plate and incubate at 4°C overnight to immobilize. Then wash the plate three times with PBST and add 200 μL / well of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0) to prepare the plate and store it at 4°C overnight.
[0144] (3) Prepare K18-328 antibody solution and K18-624 antibody solution to 5-10 ng / mL.
[0145] (4) Wash the plate three times with PBST, add 100 μL of K18-328 antibody solution or K18-624 antibody solution to each well, and shake at room temperature for 1 hour.
[0146] (5) Wash the plate three times with PBST, add 100 μL of Affinipure F(ab)'2 fragment conjugated with peroxidase diluted 15,000 times to goat anti-mouse IgG (H+L) (Jackson) to each well, and shake at room temperature for 1 hour.
[0147] (6) Wash the plate three times with PBST, add 100 μL / well of TMB Mix (1-step Ultra TMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15: 0.15: 14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction.
[0148] (7) Use a plate reader to measure the absorbance of the reaction solution at 450 nm.
[0149] Finally, the reactivity of K18-328 antibody and K18-624 antibody to the recombinant peptide composed of amino acid residues from position 239 to position 397 as shown in SEQ ID NO:9 (hereinafter referred to as "rfCK18(239-397)") (SEQ ID NO:39) was determined by a combination of immunoprecipitation and solid-phase ELISA.
[0150] <Method>
[0151] (1) Add 5 μg / mL of K18-287 antibody to 50 μL / well of ELISA plate, and immobilize it overnight at 4℃. Then wash the plate three times with PBST, add 200 μL / well of buffer I' (10 mM NaH2PO4·2H2O, 149.7 mM NaCl, 2.5 mM EDTA·2Na, 0.10% BSA, pH 7.0), and prepare K18-287 antibody solid phase plate by storing it at 4℃ overnight.
[0152] (2) Modulation of biotinylated K18-91 antibody.
[0153] (3) Prepare 15% anti-mouse IgG binding agarose 4B (CNBr-activated Sepharose 4B that binds to goat anti-mouse IgG (H+L chain)).
[0154] (4) Prepare K18-328 antibody solution and K18-624 antibody solution to 1.25 μg / mL.
[0155] (5) Prepare rfCK18 (239-397) to 50 μg / mL. Prepare CHO cell culture supernatant.
[0156] (6) Add 30 μL / well of 15% anti-mouse IgG bound agarose 4B, 30 μL / well of rfCK18 (239-397), and 30 μL / well of K18-328 or K18-624 antibody solution to each well of a 96-well V-shaped plate. Additionally, as a positive control, prepare a plate without K18-328 or K18-624 antibody solution; as a blank, prepare a plate with only 15% anti-mouse IgG bound agarose 4B.
[0157] (7) Vibrate the 96-hole V-shaped base plate at room temperature for 1 hour.
[0158] (8) Let the 96-well V-shaped plate stand for 10 minutes to allow anti-mouse IgG to bind to agarose 4B and precipitate. Then, add 50 μL / well of the supernatant from the 96-well V-shaped plate to each K18-287 antibody solid phase plate and shake at room temperature for 1 hour.
[0159] (9) Prepare a mixture of biotinylated K18-91 antibody (final concentration 2 μg / mL) and streptavidin-POD conjugate (final concentration 50 mU / mL).
[0160] (10) Wash the K18-287 antibody solid plate three times with PBST, add 50 μL / well of the mixture of biotinylated K18-91 antibody and streptavidin-POD conjugate, and shake at room temperature for 1 hour.
[0161] (11) Wash the K18-antibody solid plate three times with PBST, add 100 μL / well of TMB Mix (1-step UltraTMB-ELISA (Thermo Scientific): 3% H2O2: phosphate-citrate buffer (SIGMA) = 15:0.15:14.85) and react at room temperature for 10 minutes. Then add 100 μL / well of 1M H2SO4 to stop the reaction.
[0162] (12) The absorbance of the reaction solution at 450 nm was measured using a plate reader.
[0163] (13) Calculate the absorption rate (%) using the following formula.
[0164] Absorbance (%) = (1 - (Absorbance of antibody sample solution - Absorbance of blank) ÷ (Absorbance of positive control - Absorbance of blank)) × 100
[0165] (result)
[0166] The results are shown in Table 7. The K18-328 antibody showed binding to full-length rCK18, rfCK18 (127-430), and rfCK18 (239-396). All proteins bound by the K18-328 antibody contained peptide 17. The K18-624 antibody did not bind to full-length rCK18, rfCK18 (127-430), rfCK18 (239-396), or peptide 2, but did bind to peptide 1 and rfCK18 (239-397). The C-terminal sequences of the proteins and peptides not bound by the K18-624 antibody were not aspartic acid residues. On the other hand, the C-terminal amino acid residues of the bound proteins and peptides were aspartic acid residues. The results suggest that the presence of aspartic acid at the C-terminal amino acid residues in the peptides and proteins is important for binding to the K18-624 antibody.
[0167] Table 7
[0168]
[0169] [5] Obtaining the amino acid sequence and the specific CDR sequence
[0170] The amino acid sequences of K18-328 antibody and K18-624 antibody were obtained, and the CDR sequence was identified.
[0171] <Method>
[0172] (1) Total RNA was modulated from hybridomas that produced K18-328 and K18-624 antibodies.
[0173] (2) Use the modulated total RNA as a template to synthesize cDNA.
[0174] (3) The aptamer is ligated by RNase H double stranding.
[0175] (4) Using the obtained cDNA as a template, PCR was performed to amplify the variable region using primers and aptamer primers for the constant region of the H chain and primers and aptamer primers for the constant region of the L chain.
[0176] (5) The amplified fragments of the H chain and L chain were purified, cloned into the cloning vector, and then introduced into Escherichia coli to obtain the transformant.
[0177] (6) Modulate plasmids from the obtained transformants to obtain base sequences and amino acid sequences.
[0178] (7) Use the public CDR sequence derivation database (VBASE2) to determine the CDR sequence from the obtained base sequence.
[0179] The CDR sequence determined based on the base sequence of the K18-328 antibody is shown in Table 8. Additionally, the amino acid sequence of the variable region of the heavy chain of the K18-328 antibody is SEQ ID NO:45, and the amino acid sequence of the variable region of the light chain is SEQ ID NO:46. The CDR sequence determined based on the base sequence of the K18-624 antibody is shown in Table 9. Additionally, the amino acid sequence of the variable region of the heavy chain of the K18-624 antibody is SEQ ID NO:7, and the amino acid sequence of the variable region of the light chain is SEQ ID NO:8.
[0180] Table 8
[0181]
[0182]
[0183] Table 9
[0184] K18-624 Heavy chain (N-terminus → C-terminus) Light chain (N-terminus → C-terminus) CDR1 SFGMH (SEQ ID NO:1) RASQRIGTSI H(SEQ ID NO:4) CDR2 YISSGSTTIY YADTVKG(SEQ ID NO:2) YASESIS (SEQ ID NO:5) CDR3 RGMITTGAWF AY(SEQ ID NO:3) QQSYIWPFT(SEQ ID NO:6)
[0185] [Example 2: Comparison of the reactivity of K18-624 antibody and M30 antibody to antigen]
[0186] The reactivity of the K18-624 antibody and M30 antibody (Patent Document 1) obtained above to the antigen was determined by immunoprecipitation and Western blotting.
[0187] <Method>
[0188] (1) Load K18-624 antibody and M30 antibody (Diapharma) onto magnetic microbeads, and respectively modulate K18-624 antibody to bind magnetic microbeads and M30 antibody to bind magnetic microbeads.
[0189] (2) The culture supernatant of apoptosis-induced HepG2 cells was diluted 2 times, 10 times and 20 times with diluent (TBS, pH 7.5, 2% BSA) to prepare sample solutions.
[0190] (3) Mix the diluted sample solutions with each 0.5% antibody-bound magnetic microbead and incubate at 15 rpm, 4°C, O / N.
[0191] (4) The same procedure was performed on each 0.5% antibody-bound magnetic microbead and the pooled serum of healthy individuals.
[0192] (5) After washing the microbeads, add dissolution solution (0.05% Rapi Gest), incubate at 67℃ for 30 min, and use the supernatant for Western blot analysis.
[0193] (6) After separation by polyacrylamide electrophoresis (SDS-PAGE), the image is transferred to a PVDF membrane.
[0194] (7) Block the PVDF membrane for transcription and incubate the Fab of the K18-328 antibody prepared in Example 1 with an antibody labeled with alkaline phosphatase (K18-328Fab-ALP).
[0195] (8) Detection using chemiluminescence reaction.
[0196] (result)
[0197] The results of Example 2 are shown in Figure 2 Patent document 1 describes the M30 antibody in a lane for cell supernatant diluted 2-fold. Figure 2 In lanes (in sup×2) containing M30 antibody microbeads (IP), bands near 18 kDa were rarely observed. On the other hand, K18-624 antibody showed bands in any lane (with 2-fold, 10-fold, and 20-fold dilutions of cell supernatant)... Figure 2 A band near 18 kDa was also observed in the K18-624 antibody microbeads (IP) and lanes (denoted as sup×2, sup×10, and sup×20, respectively). This suggests that the K18-624 antibody has a higher reactivity to fCK18 in apoptosis-induced cells compared to the M30 antibody.
[0198] [Example 3: Exploration of the Expression of Calibrator Proteins]
[0199] The calibrator, expressed as a standard substance of fCK18 in E. coli, was purified. At this time, JM109 strain (Fuji Membrane & Hikari Pure Chemicals Co., Ltd.) was used in competent cells, and pBLC was used in the plasmid. The base sequence encoding amino acids 261-397 (SEQ ID NO:47) or 241-397 (SEQ ID NO:48) of the amino acid sequence shown in SEQ ID NO:9 was linked to pBLC (hereinafter, the modulated plasmids will be referred to as "pBLC-fCK18(261-397)" and "pBLC-fCK18(241-397)" respectively).
[0200] <Method>
[0201] (1) Transformants were obtained by mixing plasmids (pBLC-fCK18(261-397) or pBLC-fCK18(241-397)) in competent cells and incubating them on ice.
[0202] (2) After spreading onto Lysogeny broth (LB) agar medium, incubate (37°C, O / N).
[0203] (3) Inoculate colonies into LB liquid medium containing 100 μg / mL ampicillin and pre-culture (37℃, O / N, 300 rpm / min).
[0204] (4) Add pre-culture solution to LB medium containing 100 μg / mL ampicillin, and incubate at 37°C and 200 rpm / min until OD660 becomes 0.5-0.6.
[0205] (5) Add isopropyl β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM and incubate (37 °C, O / N, 200 rpm / min).
[0206] (6) After centrifuging the culture medium (10,000g, 4℃, 10min), the bacterial cells are washed and collected.
[0207] (7) The collected bacterial cells were resuspended in a buffer solution (Tris-buffered saline (TBS), pH 7.5), ultrasonically disrupted, centrifuged, and fractionated into soluble and insoluble fractions.
[0208] (8) The soluble fraction obtained by crushing was bound to an anti-fCK18 antibody column and the affinity chromatography was repeated twice.
[0209] (9) Use a desalting column (trade name: PD-10, Cytiva) to replace the solvent with TBS (pH 7.5).
[0210] The results of Western blotting of the soluble and insoluble fractions of rfCK18 (241-397) are shown in the figure. Figure 3 The results of Western blotting of the soluble and insoluble fractions of rfCK18 (261-397) are shown in the figure. Figure 4 The lanes for the soluble fraction of rfCK18 (241-397) ( Figure 3 Compared to the bands near 18 kDa in lanes (expressed as soluble), the lanes supplying the soluble fraction of rfCK18 (261-397) (expressed as soluble fraction) Figure 4 The band near 16 kDa in the lanes (expressed as soluble fractions) was distinct. The results suggest that when recombinant proteins were produced using *E. coli* as a host, the soluble fraction of rfCK18 (261-397) showed higher expression levels compared to rfCK18 (241-397).
[0211]
Example 4
[0212] (i) Measurement of fCK18 using the K18-624 antibody by the fully automated immunoassay apparatus HISCL (trademark) (Sysmex).
[0213] A series of assay samples (3-fold to 6561-fold dilution) were prepared by diluting apoptosis-induced HepG2 cell culture supernatant with dilution buffer (TBS, pH 7.5, 2% BSA) three-fold. fCK18 was then measured. Additionally, a calibration curve was prepared using fCK18 (261-397) prepared in Example 3 as a calibrator. fCK18 in the assay samples was measured based on the prepared calibration curve.
[0214] The fCK18 in the test sample was determined using HISCL (trademark). Furthermore, the test sample and HISCL (trademark) reagents R1-R3 were used as the solutions and volumes described below; reagents R4 and R5 (Sysmex) were commercially available. The procedure was performed according to the standard operating procedure accompanying the HISCL (trademark) reagents, using a two-step method.
[0215] Samples to be measured: 30 μL each
[0216] R1 reagent: 40 μL of diluent (TBS, pH 7.5, 2% BSA)
[0217] R2 reagent: 30 μL of 0.5% K18-624 antibody-bound magnetic beads solution
[0218] R3 reagent: 0.1 μg / mL CK18 labeled antibody (K18-328Fab-ALP) 100 μL
[0219] (ii) Determination of fCK18 by ELISA using K18-624 antibody-bound magnetic beads.
[0220] The preparation of the test samples and calibration curves was carried out in the same manner as in Example 4, and fCK18 in the samples was quantitatively determined by the following method.
[0221] <Method>
[0222] (1) Dilute 0.5% K18-624 antibody-bound magnetic beads with diluent (TBS, pH 7.5, 0.5% BSA) to prepare 0.05% K18-624 antibody-bound magnetic beads. Add 25 μL of this solution to each well of the ELISA plate, and then add 25 μL of each assay sample to each well. Incubate at 1500 rpm, RT, for 20 min.
[0223] (2) After washing the plate, add 25 μL of anti-0.1 μg / mL CK18 labeled antibody (K18-328Fab-ALP) to each well and incubate (1500 rpm, RT, 20 min).
[0224] (3) After cleaning the plate, add 50 μL of HISCL (trademark) R4 reagent per well and stir (1500 rpm, RT, 1 min). Then add 100 μL of HISCL (trademark) R5 reagent per well and stir (1000 rpm, RT, 10 sec).
[0225] (4) Use a plate reader to measure the luminous intensity.
[0226]
Comparative Example 1
[0227] The fCK18 assay using the M30 antibody was performed in the same manner as in Example 4. The fCK18 in the assay sample was measured using a commercially available fCK18 assay kit (Diapharma) by the following method.
[0228] <Method>
[0229] (1) After adding 25 μL of each sample to the ELISA plate, add 75 μL of the M30 conjugate to each well and incubate (600 prm, RT, 4 h).
[0230] (2) After washing with washing buffer, add 200 μL of TMB per well and incubate (stand still in the dark, RT, 20 min).
[0231] (3) Add 50 μL of stop solution per well and measure the absorbance at 450 nm after standing for 5 min.
[0232] (result)
[0233] The S / N ratios calculated based on the signal values measured in Example 4 and Comparative Example 1 are shown in Table 10. When the S / N ratio is set to 2 or higher as a sensitivity benchmark, Example 4(i) can detect 0.28 ng / mL or higher, Example 4(ii) can detect 0.09 ng / mL or higher, and the Comparative Example can detect 2.23 ng / mL or higher in apoptosis-induced cells. Example 4(i) shows approximately 8 times the detection sensitivity compared to Comparative Example 1, and Example 4(ii) shows approximately 24 times the fCK18 detection sensitivity compared to Comparative Example 1. This suggests that the K18-624 antibody can detect fCK18 with higher sensitivity than the M30 antibody.
[0234] Table 10
[0235] fCK18 [ng / mL] Example 4(i) Example 4(ii) Comparative Example 1 0 - - - 0.09 1.9 2.7 1.1 0.28 3.8 5.9 1.2 0.74 9.4 16.1 1.5 2.23 25.9 47.3 2.4 6.79 75.7 157.9 5.1 20.27 225.9 525.3 12.8 60.73 682.9 1848.4 37.5 182.28 2067.1 5564.2 48.3
[0236] [Example 5: Determination of fCK18 in serum]
[0237] For serum samples collected from healthy individuals, the fCK18 concentration in 20 samples was measured. Additionally, for serum samples collected from NASH patients, the fCK18 concentration in 14 samples was measured. Furthermore, the methods and conditions were the same as in Example 4.
[0238] The results of fCK18 concentration determination in healthy subjects and NASH patient subjects in Example 5 are shown in Table 11. As shown in Table 11, the fCK18 concentration in serum subjects collected from humans can also be determined.
[0239] Table 11
[0240]
[0241]
[0242] [Example 6: Measurement of Cancer Patient Subjects]
[0243] For serum samples collected from patients with various cancers, the concentration of fCK18 in three samples from each cancer patient was determined. Furthermore, the methods and conditions were the same as in Example 4.
[0244] The results of the determination of fCK18 concentration in cancer patient subjects in Example 6 are shown in Table 12. As shown in Table 12, the concentration of fCK18 in serum subjects collected from cancer patients can also be determined.
[0245] Table 12
[0246] Cancer Number of subjects Measurement range (ng / mL) Stomach cancer 3 0.77~1.66 colon cancer 3 0.84~2.41 esophageal cancer 3 0.25~1.60 Bile duct cancer 3 0.54~1.77 Breast cancer 3 0.53~16.46 lung cancer 3 0.61~1.04 pancreatic cancer 3 0.93~2.83
[0247] [Explanation of Symbols]
[0248] 11, 21: Reagent kit
[0249] 12, 22: Container 1
[0250] 13, 23: Container 2
[0251] 24: Container 3
[0252] 25: Container 4
[0253] 14, 27: Bundled boxes
[0254] 15, 26: Attached documents
Claims
1. A monoclonal antibody that binds to a cytokeratin 18 fragment comprising the amino acid sequence of SEQ ID NO: 47, wherein the antibody contains a heavy chain and a light chain, wherein... The heavy chain contains CDR1, CDR2, and CDR3, each composed of the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, and The light chain comprises CDR1, CDR2 and CDR3, each consisting of the amino acid sequences shown in SEQ ID NO: 4, 5 and 6.
2. The monoclonal antibody according to claim 1, wherein... The heavy chain consists of the amino acid sequence shown in SEQ ID NO: 7, and The light chain consists of the amino acid sequence shown in SEQ ID NO:
8.
3. The monoclonal antibody of claim 1 or 2, which binds to a peptide consisting of the amino acid sequence shown in SEQ ID NO:
10.
4. A reagent for determining cytokeratin 18 fragments, comprising the monoclonal antibody as described in any one of claims 1 to 3.
5. A kit for determining cytokeratin 18 fragments, which contains: Reagents containing the capture body Reagents containing the test subject, and Calibrator, The capture body or the detector is a monoclonal antibody according to any one of claims 1 to 3, and The calibrator contains a cytokeratin 18 fragment consisting of the amino acid sequence of SEQ ID NO:
47.
6. The kit of claim 5, wherein the calibrator comprises a plurality of reagents. Each of the plurality of reagents contains the cytokeratin 18 fragment. The concentrations of the cytokeratin 18 fragments in the plurality of reagents are different from each other.
Citation Information
Patent Citations
Apoptosis-related compounds and their use
US6296850B1
A marker comprising anti-CK8 / 18 complex autoantibody and its use for diagnosing cancer
CN103429617A
Hybridoma cell strain, anti-CK18-M30 monoclonal antibody generated by the same and application
CN108265034A
